VYVGART & VYVGART Hytrulo

What are VYVGART & VYVGART Hytrulo?

VYVGART (efgartigimod alfa-fcab) & VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) are prescription medications used to treat Myasthenia Gravis (gMG) (a condition in which the body's immune system mistakenly produces antibodies that block acetylcholine receptors at the neuromuscular junction, preventing nerve signals from reaching the muscles, leading to muscle weakness) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (a condition characterized as an autoimmune disorder in which the body attacks the myelin sheath surrounding peripheral nerves, causing weakness in the arms and limbs, numbness and tingling, loss of sensation, fatigue, and pain.

How do VYVGART & VYVGART Hytrulo work?

VYVGART (efgartigimod alfa-fcab) & VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) are fragments of an IgG antibody designed to form a strong bond with FcRn receptors. By keeping some FcRn receptors occupied, more IgG antibodies, including the harmful type, remain unattached and are then destroyed and removed. By binding to and blocking FcRn, VYVGART & VYVGART Hytrulo help clear circulating IgG antibodies that cause damage and dysfunction.

VYVGART is administered as an intravenous infusion over one hour once weekly for 4 weeks (4 infusions per cycle).

VYVGART HYTRULO is administered subcutaneously over approximately 30 to 90 seconds as once weekly injections.